Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 07:31 ET | Source: InspireMD, Inc.

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...